Skip Navigation LinksHome > March 2014 - Volume 3 - Issue 1 > New cardiovascular biomarkers in animal models: what can be...
Cardiovascular Endocrinology:
doi: 10.1097/XCE.0000000000000026
Cardiovascular Biomarkers in Animal Models - A Bridge to Human Disease Edited by Jens Peter Goetze and Lisbeth Hoier Olsen: Reviews

New cardiovascular biomarkers in animal models: what can be expected in the coming years?

Oyama, Mark A.

Collapse Box

Abstract

Animal models of disease provide the basis for important scientific inquiry of proof of concept, drug safety and efficacy, and exploration of the mechanistic and pathophysiological aspects of disease. Animals with either induced cardiac disease or spontaneously occurring cardiac disease are test beds for new cardiovascular therapies or interventions. Biomarkers in animal models can help characterize disease, stratify risk of morbidity and mortality, and serve as surrogate endpoints. Biomarkers identify important similarities and differences between the animal model and the human condition. The future of biomarkers and animal models includes cross-organ investigation using multiorgan multimarker panels. Industry will use animal models and biomarkers to help shorten the time from drug discovery to market. Biomarker development has outpaced their acceptance in clinical use and carefully designed clinical studies are needed to achieve their maximum potential.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.